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Human Goodpasture anti-a3(IV)NC1 autoantibodies share structural
determinants. To examine the structural relationship among autoantibod-
ies produced by individuals with anti-GBM antibody-mediated disease, a
polyclonal anti-idiotype directed against human anti-a3(IV)NC1 antibod-
ies was produced and then used to study autoantibodies from other
patients. For this purpose, anti-a3(IV)NC1 antibodies (anti-GBM), de-
rived from a single patient (LL) with high titer and typical anti-GBM
antibody specificity, were isolated using recombinant a3(IV)NC1-sepha-
rose affinity chromatography. Following hyperimmunization of rabbits
with anti-GBM IgG, irrelevant rabbit anti-human IgG antibodies were
removed from the antiserum using a human IgG-sepharose column. The
rabbit anti-a3(IV)NC1 antibodies (anti-Id GBM) effluent bound to
human anti-GBM antibodies, but it did not bind to either normal human
IgG or recombinant a3(IV)NC1 protein. The Id-anti-Id interaction was
conformationally dependent on intact heavy and light chains of the
anti-a3(IV)NC1 antibodies (ELISA and Western blotting). A competitive
immunoassay was developed to evaluate structural and potential genetic
relationships among anti-a3(IV)NC1 antibodies from different patients.
All patients tested (9 of 9) had a substantial fraction (producing . 50%
inhibition) of anti-GBM antibodies expressing Id-GBM. The results
indicate that shared determinants are expressed by anti-GBM antibodies
from different individuals, and they raise the possibility that common
genetic elements are used to encode them. These regions are potential
targets for design of reagents to regulate autoreactive B cells and/or
interfere with pathogenic antibody-GBM interactions, in individuals with
anti-GBM antibody mediated diseases.
Glomerulonephritis associated with pathogenic antibodies to
GBM is the prototypic organ-specific autoimmune disease [1].
Goodpasture’s disease represents a spontaneous form of this
syndrome, characterized by rapidly progressive glomerulonephri-
tis and pulmonary hemorrhage [2]. Tissue injury mediated by
circulating autoantibodies is directed against antigenic determi-
nants present within glomerular and pulmonary basement mem-
branes [3, 4].
Previous investigation has largely focused on identification of
the target antigen(s) and on the mediators that initiate and
perpetuate inflammation in this disease [5–7]. In regard to the
former, the major antigen binding region of pathogenic anti-GBM
autoantibodies has been identified to be the non-collagenous
domain of the a3 type IV collagen (a3(IV)NC1). The epitope is
formed by association of two regions of the NC1 domain of the a3
chain [8]. Mutagenic studies indicate that the end termini of the
a3(IV)NC1 domain contain major antigenic epitopes recognized
by anti-GBM antibodies [7].
Although there has been considerable progress in mapping the
disease relevant epitopes of a3(IV) collagen, the molecular and
structural properties of human anti-GBM antibodies have not
been well studied. In particular, it is not known whether there are
structural properties shared among human anti-GBM antibodies
or whether different individuals use common genes to encode
these autoantibodies. This is a goal of our studies. Our initial
experiments focus on the structural relationship among anti-GBM
antibodies from different patients with anti-GBM disease.
METHODS
Production of recombinant a3(IV)NC1 antigen
Recombinant a3(IV)NC1 antigen was produced and purified as
previously described [7]. Briefly, MC 1061 Escherichia coli con-
taining helper plasmid pDMI-1 and containing the in frame
a3(IV) cDNA were grown up in LB broth containing 10 mg/ml
ampicillin. Recombinant a3(IV) expression was then induced
using the lactose analog, IPTG. The bacteria were lysed using 6 M
guanidine HCl. Affinity purification over a nickel resin column,
employing a step-gradient elution with 25 to 250 mM imidazole in
8 M urea, was used to purify the a3(IV)NC1 peptide, which
contains six tandem histadine residues in the leader sequence
(Quiagen, Chatsworth, CA, USA). The a3(IV)NC1 peptide was
quantitated by SDS-PAGE gel electrophoresis and by the BCA
protein assay (Pierce, Rockford, IL, USA). Anti-GBM antibody
activity was assessed by ELISA as described [7].
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Immobilization of the recombinant a3(IV)NC1 antigen
To immunopurify anti-a3(IV)NC1 (anti-GBM) antibodies, an
a3(IV)NC1 agarose column was prepared by coupling recombi-
nant a3(IV)NC1 peptide to N-hydroxysuccinimide activated Af-
figel 10 resin (BioRad, Hercules, CA, USA) [9]. For this purpose
2 ml solution of recombinant a3(IV)NC1 peptide (0.6 mg/ml in 6
M urea/250 mM Imidazole) was combined with 2.5 ml of moist gel
cake, previously drained and washed with ice-cold isopropanol.
The mixture was agitated to make a uniform suspension and the
gel slurry was gently shaken overnight at room temperature.
Unreacted ester groups were blocked by adding 100 ml of
ethanolamine 1 M (pH 8) to the mixture for one hour. The gel was
transferred to a column (20 3 0.9 cm) and washed with 50 nm
acetic acid, pH 3, until the gel was free of reactants (as detected
by OD280 nm). The gel was then washed overnight with 0.1 M
Tris-HCl buffer, pH 8.8, rewashed with 2 volumes of 3 M
NaSCN/phosphate-buffered saline (PBS; elution solution), equil-
ibrated with PBS, and stored at 4°C until use.
Affinity purification of anti-a3(IV)NC1 (anti-GBM) antibodies
Recombinant a3(IV)NC1 agarose was washed twice with PBS
(10 ml/wash) until the OD280 nm of the effluent was zero. Plasma
or sera from patients with anti-GBM antibody disease, diluted 1:5
in PBS, was passed over the column three times. The column was
then rinsed with 10 to 15 bed volumes PBS until free of reactants
as assessed by OD280 nm. Bound antibodies were then eluted in
1.5 ml fractions using 3 M NaSCN/PBS (elution buffer) until the
OD280 was # 0.05. The anti-GBM antibodies were then pooled,
dialyzed against PBS, and then concentrated using a Centricon 30
(Amicon, Beverly, MA, USA). IgG concentration was measured
by OD280 and by the BCA assay (Pierce, Rockford, IL, USA) and
anti-GBM antibody activity was assessed by ELISA (see below).
As previously described, using this approach, there was complete
removal of the anti-a3(IV)NC1 antibodies from plasma aliquots
[9, and data not shown].
Production and purification of rabbit anti-idiotypes versus
human anti-a3(IV)NC1 (anti-GBM) antibodies
Two rabbits were immunized subcutaneously with 40 mg of
affinity purified anti-a3(IV)NC1 antibodies from a single patient
(LL) with high titer and typical anti-a3(IV)NC1 antibody speci-
ficity with Goodpasture’s syndrome [10], (The serum was a kind
gift from Dr. Billy Hudson.) Booster doses of 20 mg were given
every two weeks for four doses.
Irrelevant anti-human IgG activity was removed from aliquots
of the hyperimmune rabbit serum by passage over a normal
human IgG column. The column was prepared using normal
human IgG (60 mg of Cohn fraction II/III; Sigma Chemical Co.,
St Louis, MO, USA) that had been previously passed over a
recombinant a3(IV)NC1 antigen column to remove nonspecific
binding. The IgG was then coupled to protein G sepharose,
according to the manufacturer’s instructions (Immunopure Pro-
tein G IgG Orientation Kit; Pierce). The human IgG was irre-
versibly cross-linked via it’s Fc receptor to the protein G using
dimethylpimelimidate (DMP), to optimize removal of nonspecific
anti-human IgG antibody activity. The column was stored in the
dark at 4°C (the DMP crosslinker is light sensitive) in 0.02%
azide/PBS between usage.
Prior to each use the column was equilibrated with 20 ml of 10
mM Tris-HCl, pH 7.5. The rabbit anti-Id serum was diluted 1:5
with 10 mM Tris-HCl, pH 7.5, and extensively passed over the
column, until anti-human IgG was not detectable by ELISA. The
effluent was then evaluated for anti-Id GBM activity (see below).
Initial characterization of rabbit anti-Id versus human
anti-a3(IV)NC1 (anti-GBM antibodies)
Initially, the capacity of the purified rabbit anti-idiotypic serum
to bind preferentially to anti-GBM IgG was evaluated. For this
purpose, the rabbit serum was titered out on anti-GBM antibody
and normal human IgG coated wells, using a direct binding
ELISA in the following manner: Immulon 2 plates (Dynex
Technologies, Chantilly, VA, USA) were coated with 500 ng/well
of either purified anti-GBM IgG or normal human IgG in 0.05%
borate buffer overnight at 4°C. The plates were blocked with 3%
BSA in PBS (100 ml) for 1/2 hour at 37°C. Varying dilutions of
either the absorbed rabbit anti-Id-GBM serum or normal rabbit
serum were then added to individual wells (triplicates) and
incubated at 37°C for an additional two hours. After washing once
with 1% Tween/PBS and twice with PBS, goat alkaline phospha-
tase conjugated anti-rabbit IgG (1:2000; 100 ml/well) was added to
each well. The plates were incubated for 18 hours at room
temperature and then washed thoroughly and developed to
determine whether the rabbit anti-Id GBM bound preferentially
to either the purified anti-GBM antibody or normal IgG. The
results were also used to determine the appropriate dilutions of
antiserum to use in the idiotype analysis (see below).
It was essential to determine whether the purified rabbit anti-Id
contained anti-GBM antibody activity, because such activity
would interfere with interpretation of the results. To evaluate this
possibility, both Western blotting and ELISA were employed,
using previously described techniques [6, 7]. For Western blotting,
2.5 mg of recombinant a3(IV)NC1 was loaded onto a 15%
SDS-PAGE gel. The gel was run at 150 V for one hour. The
protein was then transferred at 100 V for one hour and 15 minutes
onto a nitrocellulose membrane. After transfer the samples were
incubated with anti-Id GBM in varying dilutions for 1.5 hours at
room temperature. After washing the samples were incubated at
room temperature with the appropriate secondary antibody used
at a dilution of 1:1000. (This concentration of anti-rabbit Ig had
previously been shown to be very sensitive in Western blots). The
membranes were developed using hydrogen peroxide staining.
The ELISA was performed in a manner similar to that described
above for evaluation of human anti-GBM antibody activity,
however, alkaline phasphatase labeled anti-rabbit Ig was used
instead of labeled anti-human Ig. In every case, anti-GBM serum
(1:1000) was used as the positive control, to insure that the
recombinant antigen was appropriately applied to the gel or the
plate.
Conformational analysis of the Id-anti-Id interaction
Reduced and non-reduced human anti-a3(IV)NC1 (anti-
GBM) IgG (1 mg) were resolved by SDS-PAGE (7.5%) for 1 to
1.5 hours at 150 V. The IgG was then transferred to an Immobilon
P membrane, and the membrane was blocked with TTBS contain-
ing 5% milk by gentle agitation at 4°C. After washing the
membranes thoroughly, rabbit anti-Id GBM (1:500 in blocking
buffer) was added, and the membranes were incubated for an
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Fig. 1. Preferential direct binding of rabbit
anti-Id GBM antibodies to human anti-
a3(IV)NC1 (anti-GBM) IgG. The rabbit anti-Id
GBM bound significantly greater to human
anti-GBM IgG antibodies than to normal
human IgG. Anti-idiotypic antibody activity
against human anti-GBM IgG (F) were usually
1:5000 or greater, whereas activity versus
normal human IgG (E) was never detected at
serum dilutions of greater than 1:200. Plate
blanks have been subtracted.
Fig. 2. Recombinant a3(IV)NC1 antigen is
recognized by human anti-a3(IV)NC1 (anti-
GBM) antibodies but not by rabbit anti-GBM
anti-idiotype antibodies. A total of 2.5 (20 ml)
micrograms of recombinant a3(IV)NC1 were
resolved on a 15% SDS reducing gel and
transferred to an Immobilon P membrane. The
membrane was probed using primary antibody
at a dilution of 1:100 and appropriate
secondary antibody at a dilution of 1:1000, and
then HRP stained. The rabbit anti-Id GBM did
not interact with recombinant a3(IV)NC1
indicating that an anti-anti-Id (Ab3) with anti-
GBM activity was not present in the rabbit
serum.
Fig. 3. Rabbit anti-idiotype antibodies
recognize a conformational epitope on anti-
a3(IV)NC1 (anti-GBM) antibodies. One
microgram of reduced and non-reduced human
anti-GBM IgG (lanes 2–5) and normal IgG
(lanes 6 and 7) were resolved by SDS-PAGE
(7.5%) then transferred to an Immobilon P
membrane. The membrane was probed using
rabbit a-Id GBM diluted 1:500, then
horseradish peroxidase conjugated goat anti-
rabbit IgG antibody diluted 1:1000, and then
developed using an ECL solution. The Western
blot demonstrates specificity of the Id-anti-Id
interaction. Anti-Id GBM bound to Id-GBM
(lanes 2 and 4) but not to normal human IgG
(lanes 6 and 7). Furthermore, anti-Id GBM
bound to intact anti-GBM IgG, whereas it did
not bind to either the reduced heavy or light
chains derived from the anti-GBM antibodies
(lanes 3 and 5). This result indicates that the
anti-Id GBM–anti-GBM antibody interaction is
dependent upon a conformational epitope
requiring association of heavy and light chains
of human autoantibodies. The faint bands seen
at about 150 kDa in the normal IgG lane and
at 55 kDa in the reduced lanes are due to
nonspecific cross-reactivity of the second step
reagent.
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Fig. 4. Rabbit anti-Id GBM antibodies inhibit the binding of anti-
a3(IV)NC1 antibodies to recombinant a3(IV)NC1. The results of sepa-
rate competition assays using plasma from 9 patients with anti-GBM
disease are illustrated. Dilutions of rabbit serum are indicated on the x axis
of each graph. The fraction of maximal binding is indicated on the y axis.
All 9 patients expressed the idiotype in significant quantities: the rabbit
anti-Id GBM inhibited the patients’ anti-GBM antibody activity by at least
50% in all cases. By contrast, irrelevant rabbit sera did not inhibit
anti-GBM antibody activity in any case; the results of a representative
assay are illustrated. *, negative control.
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additional 1.5 hours at room temperature. The membranes were
washed again and horseradish peroxidase conjugated goat anti-
rabbit IgG antibody was added (1:1000), incubated for an addi-
tional hour, and the membranes were developed using Enhanced
ChemiLuminescence (ECL) solution (Amersham, UK) according
to the manufacturer’s instructions.
Evaluation of anti-a3(IV)NC1 (anti-GBM) idiotype activity in
human serum
A competition idiotype immunoassay was established using
affinity-purified human anti-GBM antibodies. For this purpose,
the purified human anti-GBM antibodies were initially titered out
on recombinant a3(IV)NC1 coated wells (ELISA), as described
[8]. Briefly, Immulon 2 plates were coated with 250 ng/well of
recombinant a3(IV)NC1 antigen in coating buffer (6 M guanidine-
HCl 1 50 mM Tris-Cl, pH 7.5) for either two hours at 37°C or
overnight at 4°C. The plates were blocked with 1% BSA/PBS for
30 minutes at 37°C. Serial dilutions of serum from each patient
with anti-GBM disease was used to determine the concentration
of antibody that produced approximately 50% of maximal binding
to recombinant a3(IV)NC1 coated plates.
Varying dilutions of rabbit anti-Id GBM were then mixed with
the dilution of the human anti-GBM antibodies serum that
produced 50% of maximal activity in the direct ELISA (see
previous paragraph). After incubation for 2.5 hours at 37°C, the
mixture was transferred to recombinant a3(IV)NC1 coated plates
and then incubated for an additional hour at 37°C. After washing
(33), donkey anti-human alkaline phosphatase conjugated anti-
body (diluted 1:1000 in PBS) was added and incubated at 37°C for
one hour. The donkey antiserum had been preadsorbed with
normal rabbit Ig, and it did not have demonstrable activity against
rabbit Ig. The assay was developed with 0.05 M sodium bicarbon-
ate, 1 M MgCl2, and a 5 mg phosphatase substrate tablet (Sigma).
The plates were read after 30 and 60 minutes.
RESULTS AND DISCUSSION
As illustrated in Figure 1, rabbit anti-Id GBM bound signifi-
cantly greater to human anti-GBM antibodies than to normal
human IgG. Anti-idiotypic antibody activity against human anti-
GBM IgG was usually 1:5000 or greater, whereas activity versus
normal human IgG was never detected at serum dilutions of
greater than 1:200. The rabbit anti-Id GBM did not interact with
recombinant a3(IV)NC1 (Fig. 2), indicating that anti-anti-idio-
type with antigen binding properties shared with the original
antibody (that is, Ab3), were not present in the serum. As
importantly, the lack of rabbit anti-GBM activity facilitates inter-
pretation of the competitive inhibition studies described below.
The specificity of the Id-anti-Id interaction was confirmed by
Western blot analysis. Anti-Id GBM bound to anti-GBM but not
to normal human Ig (Fig. 3). Particularly noteworthy, anti-Id
GBM bound to intact IgG, whereas it did not bind to either the
reduced heavy or light chains derived from the human GBM
antibodies. This result indicates that the anti-Id GBM—anti-
GBM antibody interaction is dependent upon a conformational
epitope, requiring association of heavy and light chains of human
autoantibodies. Therefore the recognition site (idiotope) is
contained within the anti-GBM antibody binding region. Whether
the actual contact region is comprised of amino acids derived
from both the heavy and light chain or due to an amino acid
configuration of one chain that is facilitated by support from the
other, will require further analysis.
Competition immunoassays were then performed to determine
whether autoantibodies from other patients with anti-GBM dis-
ease were idiotypically related to the autoantibodies from the
original patient. As illustrated, 9 of 9 patients with anti-GBM
disease expressed the idiotype in significant quantities (Fig. 4):
rabbit anti-Id GBM inhibited the patients anti-a3(IV)NC1 (anti-
GBM) antibody activity by more than 50% in all patient sera,
whereas irrelevant rabbit serum did not inhibit anti-GBM anti-
body activity. These observations indicate that anti-GBM antibod-
ies from different patients share common structural determinants.
Furthermore, this determinant (idiotope) is not normally ex-
pressed by circulating immunoglobulins from normal individuals.
The results also indicate that common motifs are shared by
autoantibodies from different patients with this disease. This
finding is consistent with the conclusion that the major focus of
the anti-GBM antibody response is directed at a specific epitope on
type IV collagen. In other words, a relatively limited complementa-
rity autoantibody motif engages the disease relevant epitope. This
conclusion is consistent with our previous observations that indicate
the major antibody response is directed at a single conformation-
ally-dependent epitope within the a3(IV)NC1 domain of collagen
[7, 8]. In this regard molecular (genetic) and structural (three
dimensional) analysis of the complementary motif within anti-
GBM antibodies among different diseased individuals should be
especially revealing, since the present studies predict that they
should be related, even if different genes are used to encode these
regions.
As implied, the results have several additional implications.
First, they raise the possibility that common genetic elements may
be used to encode anti-GBM antibodies in different individuals. It
is our intention to test this hypothesis by evaluating the molecular
structure of anti-GBM antibodies from different patients with this
disease. Common genetic elements would suggest that the capac-
ity to produce anti-GBM antibodies may be genetically deter-
mined. Furthermore, whether or not common genetic elements
are used to encode anti-GBM antibodies, the idiotype relation-
ship observed among anti-GBM antibodies indicates that they
share structural determinants. This implies that therapeutic strat-
egies directed at disease relevant B cell (Ig) and/or T cell (TcR)
receptors have the potential to specifically modulate disease. In a
disease where the immune response is antigenically and idiotypi-
cally restricted, therapy targeted at these regions has the greatest
potential benefit. These avenues will be pursued in the future.
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